




<rss xmlns:a10="http://www.w3.org/2005/Atom" version="2.0">
    <channel>
        <title>Stable Ischemic Heart Disease</title>
        <link>http://www.acc.org/Feed?clinicalTopicID=24942ad7-6be3-4248-afab-2113c3c5faf5</link>
        <description>Clinical Topic Feed: Stable Ischemic Heart Disease</description>
        <language>en</language>

        

                <item>
                    <title>ACC Featured Jobs For July 2026</title>
<link>/Latest-in-Cardiology/Articles/2022/01/01/01/01/ACC-Featured-Jobs</link>                    <description>Ready to explore a new professional opportunity? Browse the list below of featured jobs and take the next step in your career!</description>
                    <pubdate>1782902880000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Optimizing Dual Antiplatelet Therapy in Patients With Diabetes and Multivessel Disease Undergoing PCI: The TUXEDO-2 Trial</title>
<link>/Latest-in-Cardiology/Articles/2026/06/08/10/20/Optimizing-Dual-Antiplatelet-Therapy</link>                    <description>The TUXEDO-2 (Ultrathin Strut vs. Xience in a Diabetic Population With Multivessel Disease 2&#226;€”India Study) trial demonstrated that among patients with diabetes mellitus and multivessel coronary artery disease undergoing percutaneous coronary intervention (PCI)...</description>
                    <pubdate>1781024040000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Managing Cardiovascular Disease in Older Adults With Cognitive Impairment: Challenges and Practical Strategies</title>
<link>/Latest-in-Cardiology/Articles/2026/06/01/13/18/Managing-CVD-in-Older-Adults-With-Cognitive-Impairment</link>                    <description>Older adults with cardiovascular (CV) risk factors or established cardiovascular disease (CVD) are at increased risk of cognitive impairment (CI). This risk is observed across several conditions, including hypertension, atrial fibrillation (AF), heart failure, and coronary artery disease.</description>
                    <pubdate>1780331400000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>AI-Enabled Clinician: Patient Engagement and Care Transformation with AI-Quantified Plaque Analysis</title>
<link>/Latest-in-Cardiology/Articles/2026/05/07/15/36/ai-enabled-clinician-07may2026</link>                    <description>In this episode, Chief Innovation Officer, Ami Bhatt, MD, FACC and Allen Taylor, MD, FACC discuss the importance of cardiovascular prevention and early screening through AI-quantified plaque analysis by drawing parallels to how oncology and gastroenterology approach early detection.</description>
                    <pubdate>1778168340000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>ORBITA Analysis: Microvascular Resistance Impacts PCI Benefit</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/05/04/11/24/ORBITA-Analysis</link>                    <description>Patients with lower microvascular resistance (MVR) saw greater placebo-controlled benefit from PCI, according to a retrospective analysis of the ORBITA trial published April 29 in JACC: Cardiovascular Interventions.</description>
                    <pubdate>1778087340000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>ACC.26 Coronary Interventional Trials</title>
<link>/Latest-in-Cardiology/Articles/2026/04/27/19/07/ACC26-Coronary-Interventional-Trials</link>                    <description>Late-breaking clinical trials presented at ACC.26 focusing on coronary interventions included several looking at intravascular guidance in complex, high-risk procedures (IVUS-CHIP), bifurcation lesions (DKCRUSH VIII), and unprotected left main PCI (OPTIMAL).</description>
                    <pubdate>1777570260000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>AI-Enabled Clinician: Engaging the Physician Community Around AI-Quantified Plaque Analysis Technology</title>
<link>/Latest-in-Cardiology/Articles/2026/04/09/13/37/ai-enabled-clinician-09apr2026</link>                    <description>In this episode, ACC Chief Innovation Officer Dr. Ami Bhatt speaks with Dr. Todd Villines about the transformative role of AI-enabled coronary CT angiogram (CCTA) and how it is expanding patient access to essential coronary artery disease (CAD) diagnostics.</description>
                    <pubdate>1775748600000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>ORBITA-CTO: Angioplasty Reduces Chest Pain, Boosts QoL in Chronic Total Occlusion</title>
<link>/Latest-in-Cardiology/Articles/2026/03/25/21/27/sun-830am-orbita-cto-acc-2026</link>                    <description>In patients with symptomatic single-vessel coronary chronic total occlusion (CTO), PCI for CTO improved angina beyond placebo, according to findings from the ORBITA-CTO trial presented at ACC.26 and simultaneously published in JACC.</description>
                    <pubdate>1774791000000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>STEMI-DTU: Left Ventricular Unloading in Anterior STEMI Without Shock</title>
<link>/Latest-in-Cardiology/Articles/2026/03/25/21/27/sat-930am-stemidtu-acc-2026</link>                    <description>Compared with immediate PCI alone, the combination of mechanical left ventricular (LV) unloading using a transvalvular micro-axial flow pump (TV-mAFP) plus delayed PCI did not reduce infarct size in patients with anterior STEMI without cardiogenic shock, according to findings from the STEMI-DTU trial presented at ACC.26 and simultaneously published in JACC.</description>
                    <pubdate>1774708320000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>DOBERMANN: Are Tocilizumab, Dobutamine Effective in Reducing CS Risk in Patients With AMI?</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/03/19/17/12/Dobermann</link>                    <description>Two brief reports in JACC on the DOBERMANN-T and DOBERMANN-D trials found that among patients with acute myocardial infarction (AMI) at increased risk of cardiogenic shock (CS), early interleukin 6 (IL 6) receptor inhibition with tocilizumab safely reduced systemic inflammation but showed inconclusive effects on NT proBNP. In contrast, early dobutamine infusion did not lower NT proBNP levels but did reduce systolic blood pressure (SBP) without raising safety concerns.</description>
                    <pubdate>1773942840000</pubdate>
                    <category>Articles and Stories</category>
                </item>

    </channel>
</rss>